Advancing Neurotherapeutics for Fragile X and Beyond with Spinogenix CMO Dr. Craig Erickson

Xtalks Life Science Podcast

In this episode of the Xtalks Life Science Podcast, Ayesha speaks with Craig Erickson, MD, chief medical officer at Spinogenix and a leading expert in translational neurodevelopmental research.

Dr. Erickson shares insights into Spinogenix’s work on restoring synapses to reverse cognitive and motor decline in conditions like Fragile X Syndrome, ALS, Alzheimer’s disease and schizophrenia.

Dr. Erickson is a Professor of Psychiatry at the University of Cincinnati College of Medicine-Affiliated and the Director of the Cincinnati Fragile X Research and Treatment Center. His work focuses on enhancing the ability to detect brain target engagement with treatment to identify meaningful functional changes in patients as early as the initial stages of human drug trials, while also determining which individuals are most likely to benefit from treatment.

Dr. Erickson holds several investigator-initiated INDs and is the inventor of several patents describing new treatment approaches. His work has been extensively supported by the NIH, CDC, US Department of Defense, stakeholder foundations and biotechnology companies from around the world.

Tune into the episode to hear Dr. Erickson discuss the evolving landscape of neurotherapeutics, early-stage drug trials and how precision biomarkers are shaping individualized treatment approaches.

For more life science and medical device content, visit the Xtalks Vitals homepage. https://xtalks.com/vitals/
Follow Us on Social Media

Twitter: https://twitter.com/Xtalks
Instagram: https://www.instagram.com/xtalks/
Facebook: https://www.facebook.com/Xtalks.Webinars/
LinkedIn: https://www.linkedin.com/company/xtalks-webconferences
YouTube: https://www.youtube.com/c/XtalksWebinars/featured